Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | USP2 | O75604 | 1/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23794464 | 0.85 | KDM4E (0.73) | KDM4EUSP2ALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL207842 | 0.83 | KDM4E (0.73) | KDM4EUSP2ALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL10282918 | 0.83 | SMN1; SMN2 (0.70) | KDM4EUSP2ALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL15331059 | 0.80 | SMN1; SMN2 (0.66) | KDM4EUSP2ALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL15219368 | 0.80 | MAPT (0.50) | KDM4EUSP2ALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL209299 | 0.77 | KDM4E (0.61) | KDM4EUSP2ALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL654947 | 0.76 | KCNA5 (0.59) | SMN1; SMN2KMT2ALMNA | |
| SCHEMBL14706944 | 0.75 | SMN1; SMN2 (0.61) | KDM4EUSP2ALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL19994399 | 0.75 | SMN1; SMN2 (0.65) | KDM4EUSP2ALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL14520832 | 0.75 | KDM4E (0.58) | KDM4EUSP2ALOX15HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963315-B1 | ENZYME INHIBITORS | CANCER REC TECH LTD (GB) | 2014-10-08 | — | — | EP | disclosed |
| US-8088761-B2 | Enzyme inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-20090247507-A1 | Enzyme Inhibitors | THE INSTITUTE OF CANCER RESEARCH (GB) | 2009-10-01 | — | — | US | disclosed |
| EP-0322296-B1 | OXIMINO-THIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTICAL USE | INSTITUT DE RECHERCHES CHIMIQUES ET BIOLOGIQUES APPLIQUEES (I.R.C.E.B.A.) Société à responsabilité limitée dite: (FR) | 1993-03-17 | — | — | EP | disclosed |
| US-4960900-A | ANTICONVULSANTS | Institut de Ercherches Chimiques et Biologiques Appliquees (I.R.C.E.B.A.) (FR) | 1990-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247507-A1 | Enzyme Inhibitors | AURKC, AURKB, AURKA | KDM4E 587/4885USP2 1502/4885ALOX15 3875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.